Omeros Corporation (NASDAQ:OMER) Receives $18.00 Average Target Price from Analysts

Shares of Omeros Corporation (NASDAQ:OMER) have received an average recommendation of “Moderate Buy” from the six ratings firms that are presently covering the company, Marketbeat Ratings reports. Two equities research analysts have rated the stock with a hold rating, three have given a buy rating and one has given a strong buy rating to the company. The average 1 year target price among brokers that have issued ratings on the stock in the last year is $18.00.

Several equities analysts have recently commented on OMER shares. HC Wainwright started coverage on shares of Omeros in a report on Tuesday, June 10th. They issued a “buy” rating and a $9.00 target price on the stock. Needham & Company LLC restated a “hold” rating on shares of Omeros in a research report on Friday, May 16th. Wall Street Zen downgraded Omeros from a “hold” rating to a “sell” rating in a research report on Friday, June 6th. Finally, D. Boral Capital reaffirmed a “buy” rating and set a $36.00 price objective on shares of Omeros in a report on Tuesday, May 13th.

Hedge Funds Weigh In On Omeros

Hedge funds have recently added to or reduced their stakes in the company. Raymond James Financial Inc. bought a new position in shares of Omeros during the fourth quarter valued at approximately $124,000. Price T Rowe Associates Inc. MD boosted its stake in shares of Omeros by 12.5% during the fourth quarter. Price T Rowe Associates Inc. MD now owns 39,582 shares of the biopharmaceutical company’s stock valued at $392,000 after purchasing an additional 4,401 shares during the period. Cerity Partners LLC increased its stake in Omeros by 9.9% in the 4th quarter. Cerity Partners LLC now owns 28,989 shares of the biopharmaceutical company’s stock worth $286,000 after buying an additional 2,600 shares during the period. Quantbot Technologies LP purchased a new stake in Omeros in the 4th quarter valued at about $46,000. Finally, Deutsche Bank AG increased its position in shares of Omeros by 38.2% during the fourth quarter. Deutsche Bank AG now owns 40,046 shares of the biopharmaceutical company’s stock worth $396,000 after acquiring an additional 11,068 shares during the period. 48.79% of the stock is currently owned by institutional investors.

Omeros Price Performance

Shares of OMER stock opened at $3.22 on Monday. The company has a market capitalization of $188.66 million, a price-to-earnings ratio of -1.22 and a beta of 2.20. The company’s fifty day moving average price is $4.92 and its 200-day moving average price is $7.56. Omeros has a one year low of $2.97 and a one year high of $13.60.

Omeros (NASDAQ:OMER) last released its earnings results on Thursday, May 15th. The biopharmaceutical company reported ($0.65) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.60) by ($0.05). Equities research analysts expect that Omeros will post -3.09 earnings per share for the current fiscal year.

Omeros Company Profile

Omeros Corporation, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting immunologic diseases, including complement-mediated diseases, cancers, and addictive and compulsive disorders. The company’s products under development include Narsoplimab (OMS721/MASP-2) that has completed pivotal trial for hematopoietic stem-cell transplant-associated thrombotic microangiopathy (TA-TMA); that is in Phase III clinical trial for the treatment of immunoglobulin A nephropathy (IgAN); and Phase II clinical trial to treat COVID-19.